Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥13 years of age~2. Clinical diagnosis of HoFH AND one of the following (a, b, or c):~   * Documented functional mutation in both LDL receptor alleles, OR~  * Skin fibroblast LDL receptor activity \<20% of normal, OR~  * TC \>500 mg/dL AND triglycerides \< 300 mg/dL AND both parents with documented TC \>250 mg/dL~3. Body weight ≥40 kg~4. Negative screening pregnancy test if female of child-bearing potential~5. Subjects must be willing and able to comply with all study-related procedures~6. Subjects must be willing and able to go off all lipid-lowering medications, dietary supplements (psyllium preparations) and LDL apheresis within 4 weeks prior to the Baseline visit until the end of the study.~Exclusion Criteria:~1. Uncontrolled hypertension defined as: systolic blood pressure \>180 mmHg, diastolic blood pressure \>95 mmHg~2. History of chronic renal insufficiency (serum creatinine \>2.5 mg/dL)~3. History of liver disease or abnormal LFTs at screening (\>3x upper limit of normal \[ULN\])~4. Any major surgical procedure occurring \< 3 months prior to the screening visit~5. Cardiac insufficiency defined by the New York Heart Association classification as functional Class III or Class IV~6. History of a non-skin malignancy within the previous 5 years~7. History of alcohol or drug abuse~8. Participation in an investigational drug study within 6 weeks prior to the screening visit~9. Serious or unstable medical or psychological conditions that, in the opinion of the Investigator, would compromise the patient's safety or successful participation in the study.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lomitapide (Type: EXPERIMENTAL): This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses

Based on this trial design, predict the completion outcome and termination type (if applicable).